Skip to content

Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening

Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening in the Community

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04927650
Enrollment
3200
Registered
2021-06-16
Start date
2015-01-08
Completion date
2026-01-31
Last updated
2025-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Carcinoma, Human Papillomavirus-Related Carcinoma

Keywords

Cervical Cancer Screening, Human Papillomavirus, HPV

Brief summary

This study examines prevention and early detection of cervical cancer through self-administration screening of patients in Western Uganda. The cervix is the opening of the uterus or womb, which is the organ that supports babies before they are born. There are simple tests that let doctors know whether or not patients have cells that may become cancer. Some of the tests determine whether patients have an increased risk for cervical disease, but they do not actually confirm that they have it: these are called screening tests. This study may help researchers determine how to best deliver cervical cancer prevention services using the HPV test.

Detailed description

PRIMARY OBJECTIVES: I. To establish the acceptance and correlates of self-collected human papillomavirus (HPV)-ribonucleic acid (RNA) testing among women in the rural Ugandan community as well as the incidence and determinants of successful completion of the cervical cancer screening cascade from self-collected HPV testing to receipt of results. II. To ascertain the frequency and determinants of successful acquisition of treatment among women who have HPV detected on self-collected swabs in rural Uganda. III. To derive population-based estimates of the prevalence of high-risk HPV and cervical intraepithelial neoplasia (CIN) detected through community-based screening employing self-collected HPV RNA testing in rural Uganda. OUTLINE: Patients receive a specimen kit for collection of HPV samples. Patients complete questionnaire before and after collection HPV samples. Patients may also participate in an interview about general ideas in improving the screening and treatment process. Patients with positive results, undergo treatment for cervical cancer.

Interventions

DIAGNOSTIC_TESTHPV testing

Undergo collection of cervical samples for HPV testing

OTHERQuestionnaire Administration

Complete questionnaires

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
University of California, San Francisco
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* Women in the three Ugandan districts (Kiboga, Kyankwanzi and Hoima) who access screening during the community health campaigns * Age 25-49 years * Resident in the study district * Provision of informed consent

Exclusion criteria

* Clinical signs and symptoms of cancer of the cervix

Design outcomes

Primary

MeasureTime frameDescription
Number of participants who complete screening1 dayThe absolute number of participants successfully completing screening.
Proportion of women 25-49 years of age who complete screening1 dayOverall proportions of women 25-49 years old successfully completing cervical cancer screening.
Proportion of participants who receive treatment after a positive screening result6 monthsProportion of participants who receive treatment after screening positive for high-risk human papillomavirus (HPV) will be calculated with a 95% confidence interval.
Proportion of participants with positive, high-risk human papillomavirus (HPV)1 dayPrevalence of participants with positive high-risk human papillomavirus (HPV)
Proportion of participants with cervical intraepithelial neoplasia (CIN2)+1 dayProportion of participants with cervical intraepithelial neoplasia (CIN2)+

Countries

Uganda

Contacts

Primary ContactJeffrey Martin, MD, MPH
Jeffrey.Martin@ucsf.edu(415) 514-8010

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026